4.3 Review

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions

Journal

ASN NEURO
Volume 1, Issue 1, Pages -

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1042/AN20090007

Keywords

GTPase; leucine-rich repeat kinase 2 (LRRK2); Lewy body; neurotoxicity; Parkinson's disease

Categories

Funding

  1. National Institute of Aging of the National Institutes of Health [AG000948-01]
  2. NATIONAL INSTITUTE ON AGING [ZIAAG000948, Z01AG000948] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Mutations in the gene encoding LRRK2 (leucine-rich repeat kinase 2) were first identified in 2004 and have since been shown to be the single most common cause of inherited Parkinson's disease. The protein is a large GTP-regulated serine/threonine kinase that additionally contains several protein-protein interaction domains. In the present review, we discuss three important, but unresolved, questions concerning LRRK2. We first ask: what is the normal function of LRRK2? Related to this, we discuss the evidence of LRRK2 activity as a GTPase and as a kinase and the available data on protein-protein interactions. Next we raise the question of how mutations affect LRRK2 function, focusing on some slightly controversial results related to the kinase activity of the protein in a variety of in vitro systems. Finally, we discuss what the possible mechanisms are for LRRK2-mediated neurotoxicity, in the context of known activities of the protein.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available